Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Systemic radioisotope therapy with I-metaiodobenzylguanidine (I-MIBG) is an effective form of targeted therapy for neuroendocrine tumors. One of the absolute contraindications to administering I-MIBG therapy listed in the 2008 European Association of Nuclear Medicine guidelines is renal insufficiency requiring dialysis, although this contraindication is not evidence based. We describe a 68-year-old woman with a metastatic small bowel neuroendocrine tumor who developed renal insufficiency requiring hemodialysis. Imaging and dosimetry with I-MIBG were performed and showed that the radiation doses to the whole body and lungs were within safe limits. She was treated with 1820 MBq of I-MIBG with no short-term adverse reactions.

          Related collections

          Author and article information

          Affiliations
          [1 ] From the *Department of Internal Medicine, University of Alberta; †Department of Diagnostic Imaging, Cross Cancer Institute; and ‡Department of Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
          Journal
          Clin Nucl Med
          Clinical nuclear medicine
          Ovid Technologies (Wolters Kluwer Health)
          1536-0229
          0363-9762
          May 2017
          : 42
          : 5
          28240668 10.1097/RLU.0000000000001601

          Comments

          Comment on this article